Ilya Pharma

Executive Summary

Ilya Pharma is a Swedish biotechnology company pioneering next-generation local-acting immunotherapies for wound healing and inflammatory skin and mucosal conditions. Founded in 2016 and based in Uppsala, the company leverages engineered lactic acid bacteria as living mini-bioreactors to produce therapeutic proteins directly at the disease site. This innovative approach aims to overcome limitations of systemic delivery and enable sustained, localized treatment. Ilya's lead program focuses on chronic wounds, a large unmet need with limited effective therapies. The platform has potential applicability across multiple inflammatory indications. The company has advanced to Phase 2 clinical development, demonstrating proof-of-concept in earlier trials. With a robust preclinical pipeline and strong IP position, Ilya Pharma represents a novel modality in the growing microbiome therapeutics space. The company's near-term value inflection points include top-line data from its ongoing Phase 2 trial in venous leg ulcers, expected in the coming year. Additionally, potential partnerships with larger pharma companies for co-development or manufacturing scale-up could provide validation and non-dilutive capital. Ilya may also seek a Series B or later-stage financing round to fund Phase 3 trials. Given its differentiated platform and progressing clinical data, Ilya Pharma is positioned for significant milestones. However, as a private company with limited public information, execution risk and competition from other wound-healing therapies warrant caution. The conviction score is 65 out of 100.

Upcoming Catalysts (preview)

• H2 2026Phase 2 top-line results in venous leg ulcers60% success
• H1 2027Partnership or licensing deal40% success
• H2 2026Series B financing round70% success